UY37065A - Método de purificación - Google Patents

Método de purificación

Info

Publication number
UY37065A
UY37065A UY0001037065A UY37065A UY37065A UY 37065 A UY37065 A UY 37065A UY 0001037065 A UY0001037065 A UY 0001037065A UY 37065 A UY37065 A UY 37065A UY 37065 A UY37065 A UY 37065A
Authority
UY
Uruguay
Prior art keywords
complexed
solution
separation material
ions
mixture
Prior art date
Application number
UY0001037065A
Other languages
English (en)
Inventor
Olsen Frenvik Janne
B Ryan Olav
Original Assignee
Bayer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer As filed Critical Bayer As
Publication of UY37065A publication Critical patent/UY37065A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/04—Processes using organic exchangers
    • B01J39/05—Processes using organic exchangers in the strongly acidic form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona un método para la purificación de 227Th complejado a partir de una mezcla que comprende 227Th complejado y 223Ra (complejado o en solución), comprendiendo dicho método: i) preparar una primera solución que comprende una mezcla de iones 227Th complejado e iones 223Ra en un primer buffer acuoso; ii) cargar dicha primera solución sobre un material de separación; iii) eluir 227Th complejado de dicho material de separación generando así una segunda solución que comprende 227Th complejado; iv) Enjuagar opcionalmente dicho material de separación utilizando un primer medio de lavado acuoso; La invención proporciona adicionalmente una solución de 227Th purificado, un producto farmacéutico y su utilización en el tratamiento de enfermedades tales como el cáncer y un kit para la generación de dicho producto.
UY0001037065A 2016-01-05 2017-01-05 Método de purificación UY37065A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1600158.8A GB201600158D0 (en) 2016-01-05 2016-01-05 Purification method

Publications (1)

Publication Number Publication Date
UY37065A true UY37065A (es) 2017-07-31

Family

ID=55406719

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037065A UY37065A (es) 2016-01-05 2017-01-05 Método de purificación

Country Status (10)

Country Link
US (2) US20190002363A1 (es)
EP (1) EP3400083A1 (es)
JP (1) JP2019509328A (es)
CN (1) CN108601991A (es)
AR (1) AR107298A1 (es)
CA (1) CA3010215A1 (es)
GB (1) GB201600158D0 (es)
TW (1) TW201726178A (es)
UY (1) UY37065A (es)
WO (1) WO2017118596A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114807636B (zh) * 2021-12-31 2023-10-20 中国工程物理研究院核物理与化学研究所 一种无载体177Lu和161Tb的GMP生产方法
WO2023159229A1 (en) 2022-02-21 2023-08-24 Bayer Healthcare Llc System, method and device for delivery of a therapeutic or diagnostic agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5035840A (en) * 1990-10-01 1991-07-30 Chemical Waste Management, Inc. Process for cleaning trace metals from EDTA
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201208309D0 (en) * 2012-05-11 2012-06-27 Algeta As Complexes
GB201310028D0 (en) * 2013-06-05 2013-07-17 Algeta Asa Pharmaceutical preparation
US9951399B2 (en) * 2014-04-09 2018-04-24 Los Alamos National Security, Llc Separation of protactinum, actinium, and other radionuclides from proton irradiated thorium target

Also Published As

Publication number Publication date
GB201600158D0 (en) 2016-02-17
AR107298A1 (es) 2018-04-18
US20190002363A1 (en) 2019-01-03
TW201726178A (zh) 2017-08-01
CN108601991A (zh) 2018-09-28
US20210130253A1 (en) 2021-05-06
CA3010215A1 (en) 2017-07-13
JP2019509328A (ja) 2019-04-04
EP3400083A1 (en) 2018-11-14
WO2017118596A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
CY1120862T1 (el) Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων
MX2017015962A (es) Uso de exosomas para el tratamiento de enfermedades.
WO2016100261A3 (en) Method of treating cancer with cgamp or cgasmp
BR112017016019A2 (pt) método para tratamento de câncer, artigo para fabricação, e, kit.
NZ730803A (en) Methods for the preparation of ribosides
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
UY36554A (es) ARNi VARIANTE
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CL2014002726A1 (es) Compuestos derivados de pirrolopirimidina y purina; composicion farmaceutica; utiles en el tratamiento del cancer (div. sol. 566-14).
EA201400178A1 (ru) Лечение рака молочной железы
CL2014000511A1 (es) Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer.
BR112017016681A2 (pt) vetor de coexpressão de vacina e moléculas coestimulatórias
PH12017550152A1 (en) Lyophilized pharmaceutical compositions
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
NI201800071A (es) Compuestos de isoindol
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
EA201790259A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
BR112017020374A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
UY37064A (es) Método de purificación
UY37065A (es) Método de purificación
AR107300A1 (es) Método para la preparación de isótopos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230601